“Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers” (2023), by Hao Zhang et al. Immunology and Microbiology research paper. Original abstract below, unchanged. A free PDF is available.

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Hao Zhang, Lin Liu, Jinbo Liu et al. · March 21, 2023 · Immunology and Microbiology

Abstract

In recent years, tumor immunotherapy has made significant progress. However, tumor immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of patients in solid cancers. The tumor microenvironment (TME) acts a significant role in tumor immunotherapy. Studies reported that tumor-associated macrophages (TAMs), as one of the main components of TME, seriously affected the therapeutic effect of PD-1/PD-L1 inhibitors. In this review, we analyzed TAMs from epigenetic and single-cell perspectives and introduced the role and mechanisms of TAMs in anti-programmed death protein 1(anti-PD-1) therapy. In addition, we summarized combination regimens that enhance the efficacy of tumor PD-1/PD-L1 inhibitors and elaborated on the role of the TAMs in different solid cancers. Eventually, the clinical value of TAMs by influencing the therapeutic effect of tumor PD-1/PD-L1 inhibitors was discussed. These above are beneficial to elucidate poor therapeutic effect of PD-1/PD-L1 inhibitors in solid tumors from the point of view of TAMs and explore the strategies to improve its objective remission rate of solid cancers.

Free PDF DOI: 10.1186/s12943-023-01725-x